Canada Markets closed

Cocaine Use Disorder Pipeline Evolves as Novel Therapeutic Assets Enter the Market

·6 min read

While there are no FDA-approved medications for the treatment of cocaine use disorder, NIDA supports a robust medication development pipeline in this area. DelveInsight’s analysis depicts a robust Cocaine Use Disorder Pipeline with 12+ active players in the domain working on 12+ pipeline therapies.

Los Angeles, USA, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Cocaine Use Disorder Pipeline Evolves as Novel Therapeutic Assets Enter the Market

While there are no FDA-approved medications for the treatment of cocaine use disorder, NIDA supports a robust medication development pipeline in this area. DelveInsight’s analysis depicts a robust Cocaine Use Disorder Pipeline with 12+ active players in the domain working on 12+ pipeline therapies.

DelveInsight’s Cocaine Use Disorder Pipeline Insights report lays down a holistic coverage of the available therapies, Cocaine Use Disorder pipeline therapies in different clinical phases of trials, pharma and biotech companies working in the Cocaine Use Disorder pipeline domain, drivers and barriers in the successful launch of the therapies, and futuristic outlook.

Some of the notable pointers extracted from the Cocaine Use Disorder Pipeline report:

  • DelveInsight’s analysis depicts a robust Cocaine Use Disorder Pipeline with 12+ active players in the domain working on 12+ pipeline therapies.

  • Key Cocaine Use Disorder pipeline therapies under investigation in different phases of clinical trials for the treatment of Cocaine Use Disorder include SBP-0069330, AFQ-056, KNX100, OMS527, AT-312, NS2359, EMB-001, and others.

  • Embera NeuroTherapeutics, Novartis, Omeros Corporation, Indivior, Saniona, KemPharm, Kinoxis Therapeutics, Camino Pharma, EryDel, Astraea Therapeutics, among several others are key prominent pharma companies working in the domain.

  • In January 2021, KemPharm announced that the US Food and Drug Administration (FDA) had completed its review of the Investigational New Drug (IND) application for KP879 (KP879 IND), concluding that the Company may proceed with its planned clinical investigation of the product candidate. KemPharm expects to initiate the clinical program for KP879 in 2021.

  • OMS405 is a small-molecule peroxisome proliferator-activated receptor gamma (PPARγ) agonist being developed by Omeros. In the peroxisome proliferator-activated receptor gamma program, the company is advancing PPARγ agonists for the treatment and prevention of addiction to substances of abuse, which may include opioids, nicotine and alcohol. As of February 10, 2021, the company owned two issued patents and one pending patent application in the US and 35 issued patents and 11 pending patent applications in foreign markets, directed to the discoveries linking PPARγ and addictive disorders.

  • In May, 2019 Tonix Pharmaceuticals in-licensed a Phase II asset, TNX-1300 (formerly known as RBP-8000) for the treatment of cocaine intoxication. TNX-1300 was developed by Columbia University, University of Kentucky and University of Michigan, and in-licensed by Tonix from Columbia University.

  • In September 2019, Kinoxis Therapeutics had been awarded a major grant from the US National Institutes of Health, National Institute on Drug Abuse (NIH/NIDA). The award has been made under The Helping to End Addiction Long-term, or NIH HEAL Initiative, with the potential of up to USD 4.6 million ($A6.8 million) of funding to support the pre-clinical and clinical development of Kinoxis Therapeutics' lead compound, KNX100, for the treatment of opioid withdrawal.

Request for Sample to know which pharma company is expected to be at the forefront in the coming years @ Cocaine Use Disorder Emerging Therapies and Forecast

The Cocaine Use Disorder Pipeline report covers the ongoing clinical trials, deals, mergers & acquisitions taking place in the domain, recent approvals and failures in space, and growth prospects across the Cocaine Use Disorder domain.

Cocaine Use Disorder Overview

Cocaine Use Disorder (CUD) is a condition that is characterized by the dependency of the person to use cocaine despite several cognitive, behavioral, and physical concerns and issues. Cocaine is a tropane ester alkaloid found in leaves of the Erythroxylum coca plant. Its use can lead to addiction and adverse physical effects, such as stroke and cardiac arrest, thus, it is classified as a Schedule II medication under the Controlled Substances Act in the United States.

Discover more about the disease, treatments, and pipeline therapies @ Cocaine Use Disorder Pipeline Assessment

Cocaine Use Disorder Pipeline Drugs

Drug

Company

Phase

MoA

RoA

EMB-001

Embera
NeuroTherapeutics

Phase II

GABA A receptor agonists; Glucocorticoid receptor antagonists

Oral

NS2359

Saniona

Phase II

Adrenergic uptake inhibitors; Dopamine uptake inhibitors;

Oral

AFQ-056

Novartis

Phase II

Metabotropic glutamate receptor 5 antagonists

Oral

OMS527

Omeros Corporation

Phase I

Type 7 cyclic nucleotide phosphodiesterase inhibitors

Oral

AT-312

Astraea Therapeutics

Preclinical

Nociceptin agonist

NA

SBP-0069330

Camino Pharma

Preclinical

Metabotropic glutamate receptor 2 and 3 modulators

Oral

CoCe erythrocyte encapsulated

EryDel

Preclinical

Enzyme replacements

NA

Request for Sample to know more @ Cocaine Use Disorder Pipeline Analysis, Key Companies, and Futuristic Trends

Cocaine Use Disorder Therapeutics Assessment

The Cocaine Use Disorder Pipeline report offers rich insights into Cocaine Use Disorder emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

By Product Type

  • Mono

  • Combination

By Stage

  • Discovery

  • Pre-clinical

  • Phase I

  • Phase II

  • Phase III

By Molecule Type

  • Peptides

  • Polymer

  • Small molecule

By Route of Administration

  • Oral

  • Intravenous

By Mechanism of Action

  • Nociceptin agonist

  • Metabotropic glutamate receptor 2 modulators

  • Metabotropic glutamate receptor 5 antagonists

  • Adrenergic uptake inhibitors

  • GABA A receptor agonists

  • Glucocorticoid receptor antagonists

  • Steroid 11-beta-hydroxylase inhibitors

  • Type 7 cyclic nucleotide phosphodiesterase inhibitors

By Targets

  • GABA A receptor

  • Glucocorticoid receptor

  • Steroid 11-beta-hydroxylase

  • Type 7 cyclic nucleotide phosphodiesterase

  • Metabotropic glutamate receptor 5

For rich insights into emerging therapies and assessment, visit Cocaine Use Disorder Pipeline Emerging Novel Therapies

Scope of the Cocaine Use Disorder Drug Pipeline Report

Coverage: Global
Key Players: Embera NeuroTherapeutics; Omeros Corporation, Novartis, Indivior, Saniona, Kinoxis Therapeutics, Camino Pharma, Astraea Therapeutics, EryDel, C4X Discovery, and others
Key Cocaine Use Disorder Pipeline Therapies: AFQ-056, KNX100, OMS527, AT-312, NS2359, EMB-001, and several others.

Discover more about the scope of the report @ Cocaine Use Disorder Emerging Therapies, Treatments, and Ongoing Clinical Trials

Table of Contents

1

Report Introduction

2

Executive Summary

3

Cocaine Use Disorder Disease Overview

4

Cocaine Use Disorder Pipeline Therapeutics Comparative Analysis

5

Cocaine Use Disorder Therapeutic Assessment

6

In-depth Commercial Assessment

7

Cocaine Use Disorder – DelveInsight’s Analytical Perspective

8

In-depth Commercial Cocaine Use Disorder Assessment

9

Cocaine Use Disorder Collaboration Deals

10

Late Stage Cocaine Use Disorder Products (Phase III)

11

Mid-Stage Cocaine Use Disorder Products (Phase II)

12

Early Stage Cocaine Use Disorder Products (Phase I)

13

Pre-clinical and Discovery Stage Cocaine Use Disorder Products

14

Inactive Cocaine Use Disorder Pipeline Products

15

Key Cocaine Use Disorder Products

16

Unmet Needs

17

Cocaine Use Disorder Market Drivers and Barriers

18

Future Perspectives and Conclusion

19

Analyst Views

20

Key Cocaine Use Disorder Companies

21

Appendix

Learn more about the report offerings @ Cocaine Use Disorder Pipeline Therapies and Emerging Trends

Audit the market before venturing with DelveInsight’s Due Diligence Services

Related Reports

Amyotrophic Lateral Sclerosis Market
DelveInsight’s ‘Amyotropic Lateral Sclerosis (ALS) - Market Insights, Epidemiology and Market Forecast– 2030’ report.
Key companies featured: Arimoclomol: Orphazyme, Biogen, Orion Pharma, Brainstorm Cell Therapeutics, AB Science, Alexion Pharmaceuticals, Cytokinetics, Biohaven Pharmaceuticals, MediciNova, Amylyx Pharmaceuticals, UCB Pharma, Clene Nanomedicine, AZTherapies, Cytokinetics/Astellas Pharma, Revalesio Corporation, Annexon, Samus Therapeutics, GlaxoSmithKline, Apellis Pharmaceuticals, Novus Therapeutics, Gilead Sciences, TikoMed AB/Neuregenix, Novartis Pharmaceuticals, PTC Therapeutics/ Dainippon Sumitomo Pharma, Ionis Pharmaceuticals/Biogen, Ionis Pharmaceuticals/Biogen

Dementia With Diabetes Market Forecast
DelveInsight’s ‘Dementia with Diabetes—Market Insights, Epidemiology and Market Forecast–2030’ report.
Key companies featured: vTv Therapeutics, Novo Nordisk

Ataxia Market
DelveInsight's "Ataxia - Market Insights, Epidemiology, and Market Forecast-2030" report.

Subarachnoid Hemorrhage Market
DelveInsight's "Subarachnoid Hemorrhage - Market Insights, Epidemiology, and Market Forecast-2030" report.

Browse through our posts
Iron Deficiency Anemia Market
Major Depressive Disorder Market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News

CONTACT: Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting